India's drug price regulator has ordered close checks on whether lower prices for 137 cancer medicines are actually reaching patients. The National Pharmaceutical Pricing Authority (NPPA) said on 13 November 2026 that State Drug Controllers must monitor manufacturers, dealers, pharmacies and hospitals, and send it Action Taken Reports by 16 November.

The order covers 137 non-scheduled anti-cancer drugs, which were brought under Trade Margin Rationalisation (TMR) through a Gazette order dated 17 October 2026. The revised prices came into force on 9 November 2026.

What the trade margin cap does

Under the October order, the margin that can be added along the supply chain for these medicines is capped at 30 per cent, according to reports carried by PTI and IANS. Because the cap applies to the gap between the price at which a drug leaves the first point of sale and the price a patient pays, it cuts the maximum retail price (MRP) printed on the pack.

An expert committee constituted by the Directorate General of Health Services under the Union Health Ministry made the recommendations on which NPPA acted, ANI reported.

How big are the price cuts?

According to an official statement reported by IANS, 85 pharmaceutical companies had reported revised MRPs by 9 November. Those covered 121 of the 137 medicines, spread across 1,366 stock-keeping units.

  • The steepest reported price reduction was 96.45 per cent.
  • More than 650 formulations saw their MRP fall by over 50 per cent.
  • Most of the reductions fell in the 50 to 75 per cent band.

The government has put the estimated saving for patients at Rs 3,541 crore. That figure was worked out by applying the gap between the old and new prices to sales volumes for April 2025 to March 2026, IANS reported.

What sellers and hospitals must do

In its 13 November release, issued through the Department of Pharmaceuticals, NPPA said manufacturers, retailers, dealers, stockists, hospitals and medical institutions must follow the revised prices. They also have to display the updated price lists prominently, both at their premises and on their websites.

The latest price lists, built from company submissions received up to 11 November, have been posted on the NPPA website and on the Pharma Sahi Daam app and portal, the regulator said.

State Drug Controllers have been told to watch the whole chain, from makers and distributors to hospital pharmacies, so that the lower MRPs are passed on. NPPA warned that any violation could attract overcharging proceedings under the Drugs (Prices Control) Order, 2013.

Why it matters

Cancer treatment often runs for months, and medicines make up a large part of what families spend. A price cut on paper only helps if pharmacies and hospital counters charge the new rate, which is why the regulator has moved from notifying prices to checking compliance within days of the new rates taking effect.

The step comes as the government highlights its record on cancer care costs. On 13 November, Prime Minister Narendra Modi shared an article by Union Health Minister J.P. Nadda on reducing the cost of anti-cancer medicines and strengthening cancer care infrastructure, saying access to quality healthcare must never be limited by affordability.

How patients can complain

Patients who are overcharged, or who cannot find a medicine, can complain through:

  • the Pharma Sahi Daam app or portal;
  • the NPPA helpline, 1800-111-255;
  • email to monitoring-nppa@gov.in.

What happens next

The Action Taken Reports from the states are due on 16 November. These are expected to show how widely the new prices have been adopted, and whether NPPA needs to begin overcharging cases against companies or sellers that have not complied. Revised prices for the 16 medicines not yet covered by company submissions are also still to be reported.

PS · Tarasna0922, CC BY-SA 4.0